Who are SHR2554; Chidamide analog tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Istodax, Chidamide+ Fulvestrant, Valproic acid, sodium salt, Low dose valproate, Vorinostat (VOR), Sodium Valproate treatment.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/shr2554-chidamide-analog-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

SHR2554; Chidamide analog tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SHR2554; Chidamide analog tablets (SHR2554; Chidamide analog tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HDAC inhibitor. Area: Oncology.

phase 3 HDAC inhibitor HDAC Oncology Small molecule Live · refreshed every 30 min

Target snapshot

SHR2554; Chidamide analog tablets (SHR2554; Chidamide analog tablets) — Jiangsu HengRui Medicine Co., Ltd.. Chidamide analog SHR2554 is an inhibitor of histone deacetylases (HDACs), which play a role in regulating gene expression.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SHR2554; Chidamide analog tablets TARGET	SHR2554; Chidamide analog tablets	Jiangsu HengRui Medicine Co., Ltd.	phase 3	HDAC inhibitor	HDAC
Istodax	ROMIDEPSIN	Teva Pharms Usa Inc	marketed	Histone Deacetylase Inhibitor	HDACs	2009-01-01
Chidamide+ Fulvestrant	Chidamide+ Fulvestrant	Liaoning Cancer Hospital & Institute	marketed	HDAC inhibitor + selective estrogen receptor degrader (combination therapy)	Histone deacetylases (HDAC) + Estrogen receptor alpha (ERα)
Valproic acid, sodium salt	Valproic acid, sodium salt	Sanofi	marketed	Histone deacetylase inhibitor; anticonvulsant; mood stabilizer	Histone deacetylase (HDAC); GABA metabolism
Low dose valproate	Low dose valproate	Mario Negri Institute for Pharmacological Research	marketed	Histone deacetylase (HDAC) inhibitor	Histone deacetylases (HDACs)
Vorinostat (VOR)	Vorinostat (VOR)	University of North Carolina, Chapel Hill	marketed	Histone deacetylase (HDAC) inhibitor	Histone deacetylases (HDAC1, HDAC2, HDAC3, HDAC6, HDAC8)
Sodium Valproate treatment	Sodium Valproate treatment	University of Pittsburgh	marketed	Histone deacetylase inhibitor; anticonvulsant	Histone deacetylase (HDAC); GABA metabolism

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HDAC inhibitor class)

Veradermics, Inc. · 2 drugs in this class
Ironshore Pharmaceuticals and Development, Inc · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Melinta Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SHR2554; Chidamide analog tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/shr2554-chidamide-analog-tablets. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab